Europe’s medical devices industry saw a drop of 24.24% in deal activity during May 2021, when compared with the last 12-month average, led by Murano Bidco’s $1.36bn acquisition of Vectura Group, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 25 medical devices industry deals worth $2.6bn were announced for the region in May 2021, against the 12-month average of 33 deals.
Of all the deal types, venture financing saw most activity in May 2021 with 13 transactions, representing a 52% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with seven deals, followed by private equity deals with five transactions, respectively capturing a 28% and 20% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $1.91bn, while private equity and venture financing deals totalled $383.58m and $292.02m, respectively.
Europe medical devices industry deals in May 2021: Top deals
The top five medical devices deals accounted for 89.4% of the overall value during May 2021.
The combined value of the top five medical devices deals stood at $2.31bn, against the overall value of $2.6bn recorded for the month.
The top five medical devices industry deals of May 2021 tracked by GlobalData were:
1) Murano Bidco’s $1.36bn acquisition of Vectura Group
2) The $390m acquisition deal with Inivata by NeoGenomics
3) IP Group, M&G Investments, Nikon, Temasek Holdings (Private) and Wellington ManagementLLP’s $280.17m private equity deal with Oxford Nanopore Technologies
4) The $155m acquisition of Immunodiagnostic Systems by PerkinElmer
5) HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures’ venture financing of Huma Therapeutics for $130m.
